

This invention concerns a treatment of lymphoma of V-cells by use of chimeric and labeled antibodies with radioactive isotopes for binding with surface antigen of Bp35 ("CD20") V-cell.

Radionuclide emits radioactive particles, which may damage a cellular DNA to the stage, at which cellular mechanisms of reparation are not able provide vital activity of cell; therefore radioactive label destroys preferably tumor cells. The use of labeled antibodies with radioactive isotopes according to determination comprises radioactive substance, which requires respecting precautions both for patient (e.g. in possible transplantation of bone marrow), and for service personnel (i.e. a necessity of providing a high degree of safety while working with radioactive substances).